This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
by Zacks Equity Research
Editas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data.
EDITNegative Net Change RGENPositive Net Change LQDAPositive Net Change HRMYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress
by Zacks Equity Research
IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.
IMVTPositive Net Change ALTPositive Net Change LQDAPositive Net Change HRMYNegative Net Change
biotechs
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
by Zacks Equity Research
MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
MIRMPositive Net Change INCYPositive Net Change RGENPositive Net Change LQDAPositive Net Change
biotechs earnings
RXRX Q2 Earnings Miss Estimates, Revenues Fall Y/Y, Stock Down
by Zacks Equity Research
Recursion misses Q2 earnings and revenue estimates as collaboration revenues fall year over year, sending shares lower while pipeline and partnership programs advanced.
RXRXPositive Net Change RHHBYPositive Net Change RGENPositive Net Change HRMYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness
by Zacks Equity Research
ADMA Biologics matches earnings estimates, misses on revenues and maintains its 2026 outlook as strong Asceniv growth offsets continued pressure on Bivigam.
ADMANegative Net Change NVAXPositive Net Change LQDAPositive Net Change HRMYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark
by Zacks Equity Research
UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that reshape future growth.
UTHRPositive Net Change MNKDPositive Net Change LQDAPositive Net Change HRMYNegative Net Change
biotechs
HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up
by Zacks Equity Research
HRMY tops Q2 estimates as Wakix demand fuels 30% revenue growth. A growing pipeline, BP-205 progress and reaffirmed 2026 guidance add momentum.
HRMYNegative Net Change NVAXPositive Net Change LQDAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut
by Zacks Equity Research
PCRX beats Q2 earnings estimates as higher product sales boost revenues, with Exparel demand and portfolio momentum supporting growth despite a guidance cut.
PCRXNegative Net Change RGENPositive Net Change LQDAPositive Net Change
biotechs earnings
AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure
by Zacks Equity Research
Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.
AMGNPositive Net Change AZNPositive Net Change NVOPositive Net Change LLYNegative Net Change
biotechs pharmaceuticals
Ultragenyx's Q2 Earnings Beat Estimates, Revenues Jump Y/Y
by Zacks Equity Research
RARE beats Q2 earnings estimates as revenues surge year over year to a record quarterly high, driven by higher product sales across its portfolio.
RAREPositive Net Change REGNPositive Net Change RGENPositive Net Change LQDAPositive Net Change
biotechs earnings